knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 13:10:20 - browse：791

Doctor sitting at a crowded desk. -- first opinion coverage from STAT — Adobe

SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of the J.P. Morgan Healthcare Conference, it’s that they’ve all but abandoned the prospect of making significant profit on patient care. Instead, they’re fully throwing their weight into other ways of making money — things like developing drugs or selling insurance.

Making money outside of patient care — or “revenue diversification,” if you prefer industry jargon — has always made appearances on hospital slides at the annual investor conference in San Francisco. This year, though, hospital executives are projecting a sense of urgency around growing profit in other areas to make up for losing money on their bread and butter: taking care of patients in hospitals.

“It used to be nice to have, but now it’s a must-have, especially for not-for-profit health systems,” Niyum Gandhi, the chief financial officer of Boston’s Mass General Brigham said in an interview with STAT after his presentation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： WuXi out of biotech trade group, U.S. and China relations to blame

explore

WSS

Health tech investors get more selective as pandemic boom fades

Health tech investors get more selective as pandemic boom fades

STAT Summit: How researchers deal with rejection

FDA clears Verve to begin U.S. study of gene

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

UCLA team creates talking throat patch for voice disorders

leisure time

knowledge

entertainment

In age of alternative facts, a scholarly course on calling out crap

Pushing for an NIH office for post

Alkermes shareholders re

As AI in medicine takes off, can 'human in the loop' prevent harm?

Medicare proposal to cover medical devices draws a mixed reaction

EPA limits use of carcinogenic gas for sterilizing medical devices

Trump demands the U.S. pay no more for drugs than other countries … again

Why scientists need input from humanists on sensitive research

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Bristol, Sangamo, Gilead, and more

focus

Change Healthcare outage fallout shows need for new oversight

Study on Amgen’s bispecific immunotherapy produces positive data

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Health tech investors get more selective as pandemic boom fades

Ebola: Gilead Sciences antiviral shows promise as new treatment

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Wikipedia

explore

hotspot

leisure time